Literature DB >> 10235153

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

M M Manos1, W K Kinney, L B Hurley, M E Sherman, J Shieh-Ngai, R J Kurman, J E Ransley, B J Fetterman, J S Hartinger, K M McIntosh, G F Pawlick, R A Hiatt.   

Abstract

CONTEXT: A Papanicolaou (Pap) test result of atypical squamous cells of undetermined significance (ASCUS) presents a clinical challenge. Only 5% to 10% of women with ASCUS harbor serious cervical disease, but more than one third of the high-grade squamous intraepithelial lesions (HSILs) in screening populations are identified from ASCUS Pap test results.
OBJECTIVE: To determine whether human papillomavirus (HPV) DNA testing of residual material from liquid-based Pap tests and referral of cases found to be HPV-positive directly to colposcopy could provide sensitive detection of underlying HSILs in women with ASCUS Pap results, compared with repeat Pap testing. DESIGN AND
SETTING: Natural history of women with ASCUS Pap smear results, all of whom had liquid-based cytology, HPV testing, and subsequent repeat Pap tests and colposcopy with histologic evaluation, conducted at 12 gynecology clinics in a large managed care organization between October 1995 and June 1996. PARTICIPANTS: From a cohort of 46009 women who had routine cervical examinations, 995 women with Pap test results of ASCUS who consented to participate were identified. MAIN OUTCOME MEASURES: Cervical histology, HPV test results, and repeat Pap smear results, and sensitivity of HPV testing to identify patients found to have HSIL+ histology.
RESULTS: Of 995 participants with ASCUS Pap test results, 973 had both a definitive histologic diagnosis and HPV result. Sixty-five (6.7%) had histologic HSIL or cancer. For women with histologic HSIL+, the HPV test was positive in 89.2% (95% confidence interval [CI], 78.4%-95.2%), and the specificity was 64.1 % (95% CI, 60.9%-67.2%). The repeat Pap smear result was abnormal in 76.2% (95% CI, 63.5%-85.7%). Triage based on HPV testing only or on repeat Pap testing only would refer similar proportions (approximately 39%) to colposcopy. The sensitivity of HPV DNA testing for HSIL was equivalent to, if not greater than, that of the repeat Pap test. We further estimated that an HPV-based algorithm including the immediate colposcopy of HPV-positive women, and then repeat Pap testing of all others, would provide an overall sensitivity of 96.9% (95% CI, 88.3%-99.5%).
CONCLUSIONS: For women with ASCUS Pap tests, HPV DNA testing of residual specimens collected for routine cervical cytology can help identify those who have underlying HSIL. By testing the specimen collected at initial screening, the majority of high-risk cases can be identified and referred for colposcopy based on a single screening.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235153     DOI: 10.1001/jama.281.17.1605

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  61 in total

1.  HPV testing for clarifying borderline cervical smear results.

Authors:  M M Manos
Journal:  BMJ       Date:  2001-04-14

2.  Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study.

Authors:  G Rebello; N Hallam; G Smart; D Farquharson; J McCafferty
Journal:  BMJ       Date:  2001-04-14

Review 3.  Cervical cytology after 2000: where to go?

Authors:  C J Meijer; J M Walboomers
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

4.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

5.  Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.

Authors:  A Lytwyn; J W Sellors; J B Mahony; D Daya; W Chapman; N Ellis; P Roth; A T Lorincz; A Gafni
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

6.  Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium.

Authors:  B R Wood; L Chiriboga; H Yee; M A Quinn; D McNaughton; M Diem
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

7.  Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types.

Authors:  Tarik Gheit; Stefano Landi; Federica Gemignani; Peter J F Snijders; Salvatore Vaccarella; Silvia Franceschi; Federico Canzian; Massimo Tommasino
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

8.  Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens.

Authors:  Véronique Fontaine; Corinne Mascaux; Christine Weyn; Aurore Bernis; Nathalie Celio; Philippe Lefèvre; Leonard Kaufman; Christian Garbar
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

Review 9.  Epidemiology of HPV-associated oropharyngeal cancer.

Authors:  Kristen B Pytynia; Kristina R Dahlstrom; Erich M Sturgis
Journal:  Oral Oncol       Date:  2014-01-22       Impact factor: 5.337

10.  The laboratory diagnosis of genital human papillomavirus infections.

Authors:  François Coutlée; Danielle Rouleau; Alex Ferenczy; Eduardo Franco
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-03       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.